Innovent's innovative PD-1 inhibitor, Tyvyt (sintilimab), is a fully human IgG4 monoclonal antibody developed in collaboration with Eli Lilly. The immunotherapy is not FDA-approved yet. However, it has bagged regulatory approvals in China for three indications so far; relapsed/refractory classical Hodgkin lymphoma, non-squamous non-small cell lung cancer (nsqNSCLC), and recently for squamous NSCLC.

At the 2021 ESMO Annual Meeting, initial data were presented from two clinical trials evaluating sintilimab in combination with chemotherapy against two new cancer indications. Results from the Phase 3 ORIENT-15 and ORIENT-16 trials show that sintilimab plus chemotherapy significantly improved outcomes in esophageal and gastric cancer patients, respectively.